Special Offers & Promotions
Laboratory Automation & IT Solutions
MetaboParis-Sant?platform first in France to install Bruker In Vitro Diagnostic research by NMR system at Universit?de Paris
Universit?de Paris has installed a new Bruker In Vitro Diagnostic research (IVDr) nuclear magnetic resonance (NMR) spectrometer within its MetaboParis-Sant?platform located in the center of Paris city, France. One of the most prestigious universities in France, known for its cutting-edge research in medicine and more broadly biology and health, is the first facility in the country to benefit from a IVDr instrument of its kind. MetaboParis-Sant? is upheld as a national center of excellence for the metabolic analysis by NMR of human biofluids.
Thanks to the Bruker IVDr technology, Universit? de Paris can now analyze human samples, such as plasma, serum, or urine, to automatically obtain their composition and identify the main metabolites present, more than one hundred parameters, all in less than 15 minutes.
The new IVDr system is an asset in supporting the diagnosis of conditions that present a major public health issue: “Blood analyses will, for example, make it possible to make a better assessment of cancer such as lymphoma by establishing a more detailed lipid profile than that provided by conventional biological analysis methods,” explains Dr. Gildas Bertho, Scientific Director of the MetaboParis-Sant? platform. He continues: “Our work with academic, industrial, and medical laboratories is what makes us so unique, and we recognize the role of Bruker in supporting these collaborations.”
Claire Cannet, Market Manager for Clinical RTD at Bruker BioSpin: "Bruker is proud to support the NMR community further and drive advanced research in the clinical research field. The MetaboParis-Sant? platform represents a huge step for innovative disease analysis and, through its partnerships, together we are furthering knowledge into molecular phenomics questions."
The MetaboParis-Sant? project has established partnerships with Assistance Publique–H?pitaux de Paris (AP-HP) and other hospitals throughout France to use and promote NMR technology, leading the way in research. It benefits from a national network of scientific collaborations supported by the ?le-de-France region, the French National Centre for Scientific Research (CNRS) and the French National Institute of Health and Medical Research (Inserm), and, at present, is engaged in two major national cohort studies in the fight against cancer and COVID-19. Now that NMR has been established as a crucial technique within the MetaboParis-Sant? project, it is the first step to revolutionize routine biological analysis in French laboratories.
MetaboParis-Sant is a metabolomic platform located in the NMR department (Dir G. Bertho) of UMR8601 CNRS and administered by the UMS BioMedTech Facilities - Inserm US36 | CNRS UMS2009 | Universit? de Paris. It deals with requests for biological analyzes from the private and public sectors, mainly for metabolomics studies. This platform relies on the spectroscopic expertise developed in the NMR of Biological Substances research team (Dir N. Giraud) working with complex sample analysis strategies in the context of scientific collaborations. This IVDr equipment, improved protocols, and the strong expertise of the NMR staff in metabolomics brings together a large range of key players from academic, industrial, and medical laboratories from hospitals.
About Universit de Paris
Universit? de Paris is one of the leading research-intensive universities in France (4th in the ARWU ranking, 1st in the Leiden ranking for the 1% of the most cited publications). Across a broad range of disciplines that include health sciences, formal and experimental sciences and the humanities and social sciences, Universit? de Paris builds on the highest quality disciplinary research to cultivate multi and interdisciplinary collaborations in research and education. Universit? de Paris is composed of three Faculties (Health, Sciences and Humanities and Social sciences), a component institution, the Paris Institute of Earth Physics, (IPGP) and now a partner research organization, the Institut Pasteur. Universit? de Paris has 63,000 students, 7,500 teacher-researchers and researchers, 21 doctoral schools and 119 research units.
About Bruker Corporation
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.